Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312

Salt-inducible kinases (SIKs) SIK1, SIK2, and SIK3 are serine/threonine kinases and form a subfamily of the protein kinase AMP-activated protein kinase (AMPK) family. Inhibition of SIKs in stimulated innate immune cells and mouse models has been associated with a dual mechanism of action consisting of a reduction of pro-inflammatory cytokines and an increase of immunoregulatory cytokine production, suggesting a therapeutic potential for inflammatory diseases. Following a high-throughput screening campaign, subsequent hit to lead optimization through synthesis, structure–activity relationship, kinome selectivity, and pharmacokinetic investigations led to the discovery of clinical candidate GLPG3312 (compound 28), a potent and selective pan-SIK inhibitor (IC50: 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3). Characterization of the first human SIK3 crystal structure provided an understanding of the binding mode and kinome selectivity of the chemical series. GLPG3312 demonstrated both anti-inflammatory and immunoregulatory activities in vitro in human primary myeloid cells and in vivo in mouse models.


■ INTRODUCTION
The salt-inducible kinase (SIK) family comprises three isoforms (SIK1, SIK2, and SIK3) that belong to the AMPactivated protein kinase (AMPK) family of serine/threonine protein kinases. 1 SIKs have been implicated in the regulation of several physiological processes, including circadian rhythms, bone formation, skin pigmentation, metabolism, and modulation of inflammatory cytokine production.Consequently, the potential of SIK inhibitors has drawn interest in various therapeutic areas. 2 Several SIK inhibitors such as compounds 1−7 (Figure 1) have been reported and used to investigate SIK biology in vitro and in vivo.As frequently observed with kinase inhibitors, compounds 1−7 also inhibit numerous other kinases that may limit their potential therapeutic applications (Table 1).
In healthy individuals, a tightly regulated balance of pro-and anti-inflammatory pathways maintains immune homeostasis.However, in inflammatory diseases, imbalances in proinflammatory versus immunoregulatory processes cause chronic inflammation, which, if left untreated, leads to tissue damage in the body.Despite a broad range of treatment options in inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), many patients do not achieve full remission, highlighting a significant unmet medical need. 3−5 Myeloid cells play key roles during the initiation, propagation, and resolution of inflammation.The SIKs control gene regulation and act as a molecular switch, and inhibition has been shown to reprogram myeloid cell types to an immunoregulatory phenotype. 6−9 The evaluation of pharmacological pan-SIK kinase inhibitors 1−4 (Figure 1) in in vitro macrophage and dendritic cell models stimulated with Toll-like receptor (TLR) 2 or TLR4 ligands has been shown to reduce the release of tumor necrosis factor (TNF) α and interleukin (IL) 12 and to stimulate the production of antiinflammatory mediators, such as IL-10. 6,8,9Consistent with in vitro observations, intraperitoneal dosing of compound 5 to mice prior to lipopolysaccharide (LPS) challenge was found to lead to a reduced abundance of TNFα and increased IL-10 levels in the serum of mice relative to controls.More recently, intraperitoneal administration of HG-9-91-01 (3) in mouse models of colitis led to an improvement of the disease score coupled with a decrease of TNFα and IL-12, and an increase of IL-10 in colonic tissues. 10 Altogether, this body of evidence suggests that selective SIK inhibition is an attractive therapeutic approach for the treatment of inflammatory diseases such as IBD.We embarked on a drug discovery program with the goal to identify a potent pan-SIK inhibitor with excellent kinome selectivity and suitable pharmacokinetic and ADMET properties for in vivo evaluation after oral dosing and for further preclinical development.
Here, we report the identification of a new chemotype for SIK inhibition, the first X-ray crystal structure of SIK3 that enabled an understanding of the binding mode and selectivity of the new chemotype, and the optimization of kinase selectivity and pharmacokinetic properties that led to pan-SIK inhibitor clinical candidate GLPG3312.
We theorized that the carboxamide group possibly interacts in the phosphate binding region of multiple kinases, and such moiety can serve as an off-target pharmacophore, hence replacement and alkylation of the carboxamide group were investigated.Replacement of this group by a methyl ester (11) or a carboxylic acid (13) led to a 10-fold or more drop of potency against SIKs, suggesting a contribution of the hydrogen bond donor group of the amide to the potency of compound 10 on SIKs (Table 3).Substitution of the carboxamide by a hydroxymethyl group containing such a hydrogen bond-donating group (12) only showed a 2-to 4fold decrease of activity.The SAR was found to be distinct

Journal of Medicinal Chemistry
between off-target kinases; for example, replacement of the carboxamide group (10) by a methyl ester (11) led to a more than 100-fold decrease in activity against AMPK but had no impact on activity against FMS.In contrast, replacement of the carboxamide group (10) by a carboxylic acid had a minor impact on the activity against AMPK but led to more than a 40-fold drop of activity against FMS.Compound 12 had an interesting profile, retaining potent activity below 10 nM on SIKs and improved selectivity against ALK5, AMPK, LynA, and TGFβR2.As further selectivity improvement was desired against ABL1 and FMS, alkylation of the amide group was investigated next to assess whether off-target activity could be decreased by a steric clash in this region.
Secondary and tertiary amides of compound 10 were prepared and evaluated (Table 4).Introduction of a small substituent such as methyl (14) or ethyl (15) led to a 3-to 12fold loss of potency against SIKs and a more than 20-fold drop of activity against ALK5, AMPK, and TGFβR2.In contrast, bulkier substituents, such as in trifluoroethyl (16) and cyclopropyl (17), retained similar potency against SIK3 to 10 and slightly decreased activity on SIK1 and SIK2.Trifluoroethyl (16) and cyclopropyl (17) analogues also led to further improvement of selectivity against off-target kinases ABL1, ALK5, and LynA compared with 10, 14, and 15.A further increase of the size of the substituent with a tert-butyl group (18) caused a major loss of activity against SIKs likely due to a steric clash and resulted in micromolar activity against   amide.Modification of the methoxy groups was also investigated as an option to impact potency and off-target selectivity.Interestingly, replacing one of the methoxy groups on the phenyl ring by a difluoromethoxy group in compound 20 gave a 3-fold gain of potency against SIKs compared with 15 and decreased activity against the six off-target kinases, in particular AMPK with an IC 50 superior to 4 μM.Compound 20 displayed similarly low nanomolar activity against SIKs as 10 and an IC 50 above 150 nM for all the off-target kinases identified for 10.As depicted in the next section, the difluoromethoxy group can make a hydrogen bond interaction in SIKs and lead to a steric clash in other kinases such as AMPK, leading to improvement of on-target potency and offtarget selectivity.In summary, exploration of the SAR of the benzamide moiety led to the identification of trifluoroethyl (compound 16) and cyclopropyl (compound 17) moieties as amide substituents, providing high potency on SIKs and improved selectivity against off-targets compared to unsubstituted amide.Introduction of a second methoxy group on the phenyl ring in the ortho position of the carboxamide moiety increased potency on SIKs, and replacement of one of the methoxy groups by a difluoromethoxy group led to a gain of potency on SIKs and enhanced selectivity against off-targets (compound 20).
The SAR around the pyrazole group was also explored to understand the impact on potency and selectivity using 15 as the basis, and the results are shown in Table 5. Shortening of the ethyl group to a methyl group as in 21 retained similar activity against SIKs and selectivity against off-targets as 15.
Introduction of a hydrogen bond-donating group in hydroxyethyl (22) and methyl carboxamide (23) derivatives also retained activity against SIKs but also increased selectivity against ABL1, ALK5, and TGFβR2.Other substitutions such as cyanomethyl (24), methoxyethyl (25), and 4-tetrahydropyranyl (26) did not bring further improvement on potency against SIKs or on selectivity against off-targets.Overall, substitution of the pyrazole ring with alkyl groups bearing hydrogen bond-accepting and hydrogen bond-donating groups as in compounds 22−26 was found to have a limited impact on SIK activity consistent with a moiety pointing toward the solvent region as described in the next section.The improvement of selectivity against ABL1, ALK5, and TGFβR2 off-target kinases may result from a different environment and less flexibility in this region in these kinases compared to SIKs.
Co-crystal Structure of SIK3 with 22.To our knowledge, no crystal structure from the SIK family has been reported, and we disclose here the first experimentally determined crystal structure from the SIK family.The crystal structure of SIK3 (60-394 T221D) in a complex with 22 was determined to 3.1 Å.The structure contains a classical bilobed kinase catalytic domain with a flexible hinge region connecting the two lobes and forming a hydrophobic cleft serving as the binding site for ATP where compound 22 is bound (Figure 2A).The Nterminal lobe consists of five β-sheets and one α-helix called αC.The first two β-sheets (called β1 and β2) are linked by a loop (P-loop), which confers additional flexibility to this region (Figure 2B).The Cterminal lobe is mainly α-helical and contains a tripeptide motif, DFG (Asp-Phe-Gly), that marks the beginning of the activation segment (A-loop).Kinases can adopt catalytically active or inactive conformations that regulate their function. 19In the active conformation, the aspartate of the DFG motif points into the ATP-binding site (DFG-in conformation), and in the inactive conformation, it points to the back-pocket (DFG-out).The second key feature of the active conformation for kinases is the orientation of the αC helix, which in an active state is rotated inward toward the active site (αC-helix-in).In the crystal structure, the kinase domain of SIK3 adopts an active-like conformation (DFG-in, αC-helix-in).The kinase catalytic domain is connected by a linker to an α-helical ubiquitin-associated (UBA) domain.The linker contains an α-helical segment which is locked in place via both hydrophobic and electrostatic interactions with the kinase C-lobe (Figure 2C).The UBA domain packs onto the N-terminal lobe of the catalytic domain, forming an extensive interface consisting of 536 Å 2 in buried surface area, 20 distal to the catalytic cleft where 22 is located (Figure 2D,E).This domain arrangement closely resembles that of other AMPKrelated kinase (ARK) family members (MARK1−4) (Figure 2F). 21−24  As mentioned above, compound 22 binds in the ATP site with the protein adopting an active-like conformation (DFGin, αC-helix-in) and as such can be classed as a type 1 kinase inhibitor.The benzimidazole nitrogen of 22 establishes a hydrogen bond interaction with the backbone NH of Ala145 at the hinge (Figure 3).The phenyl ring is out of plane relative to the benzimidazole scaffold, and the side chains of Val80 and Ala205 provide lipophilic contacts to the substituted phenyl group.The electron density maps support the modeled orientation of the ethyl amide chain, pointing toward the solvent region.The amide group forms a hydrogen bond contact with Lys95 but not with Asp206.The proximity of the NH of the amide group and the methoxy substituent on the phenyl ring suggests that in a flexible environment an internal hydrogen bond interaction could occur, helping the orientation of the carbonyl group of the amide to interact with Lys95.The pyrazole ring is coplanar with the benzimidazole scaffold, allowing a displaced π−π interaction with Tyr144 and a weak hydrogen bond between the slightly polarized C−H group of Hydrogen bond interactions are shown as dotted yellow lines.A feature-enhanced map contoured at 1.0σ around the ligand is displayed as a blue mesh.The tip of the ligand hydroxyethyl chain is not well resolved, and the hydroxyl group is suitably positioned to form hydrogen bonds with either the backbone carbonyl of Ser146 or the side chain of Tyr144.
the pyrazole and the carbonyl moiety of Ala145.The ligand hydroxyethyl group is suitably positioned to form hydrogen bonds with either the backbone carbonyl of Ser146 or the side chain of Tyr144, but the hydroxy tip is not well resolved in this structure, suggesting a weak interaction.The presence of the hydroxyl group in 22 is not related to a boost in potency compared with the ethyl group in 15 or methyl group in 21, suggesting the weakness of the hydrogen bond interaction either with Ser146 or Tyr144.Another hypothesis to rationalize this effect could be that the addition of the hydroxyl group changes the hydration network in this solventexposed region, balancing the positive effect of the hydrogen bond between the ligand and target.
The crystal structure enabled analysis of the effects of different substitutions on selectivity and potency of the compounds by comparison with structures of other kinases.Kinases contain a single residue in the ATP-binding site, known as a gatekeeper residue, that separates the adenine binding site from an adjacent hydrophobic pocket usually called back-pocket.When one of the methoxy groups of compound 15 is replaced by a difluoromethoxy moiety in compound 20 (Table 4), a loss of activity against AMPK was observed.A likely explanation is the difference of the gatekeeper residue between the SIK family and AMPK.In the SIK family, the threonine gatekeeper (SIK3 Thr142) results in a back-pocket that can accommodate the methoxy and difluoromethoxy groups (Figure 4A,B).In contrast, the presence of a methionine gatekeeper (Met95) in AMPK reduces the volume of the back-pocket, leading to a possible clash with the larger difluoromethoxy group, whereas the methoxy group would be tolerated (Figure 4C,D).Moreover, potential interaction through a hydrogen bond between the polarized hydrogen of the difluoromethoxy moiety and the hydroxyl group of the side chain of the threonine gatekeeper in the SIK family (SIK3 Thr142, Figure 4A) could explain the increased potency observed for 20 compared to 15.
The crystal structure also revealed possible reasons for the impact of amide alkylation on the off-target selectivity (Table 4).These alkyl groups could point toward the top part of this pocket region, occupying the bottom part of the P-loop.Ethyl 15, trifluoroethyl 16, and cyclopropyl 17 groups are well tolerated in SIKs because of their size; however, the bulkier tert-butyl 18 is not, likely due to steric hindrance in this small pocket.As hypothesized in previous publications, the P-loop could play a key role in ligand binding and selectivity, 25,26  providing a potential explanation of the impact of these substituents on the off-target selectivity.Second alkylation of the amide in 19 is not tolerated, as it increases steric bulk and leads to loss of the possible internal hydrogen bond between the −NH of the amide and the oxygen of the methoxy substituent.
In summary, we report the first crystal structure of SIK3 kinase and UBA domains in complex with compound 22.The kinase domain of SIK3 adopts an active-like conformation (DFG-in, αC-helix-in), and compound 22 occupies the ATP binding site and hence can be classified as a type 1 kinase inhibitor.Compound 22 is stabilized in SIK3 by the hydrogen bond interactions between one nitrogen of the benzimidazole scaffold and the backbone NH of an alanine residue at the hinge, as well as between the carbonyl of the amide group of 22 and the side chain of a lysine residue.Additionally, lipophilic contacts in the binding site made between the substituted phenyl ring and hydrophobic residues and an aromatic interaction between the pyrazole ring and tyrosine side chain in the hinge result in high potency for this chemical series.
Compound 20 having a difluoromethoxy group as the replacement of a methoxy group was docked and highlighted a possible hydrogen bond interaction between the polarized hydrogen of the difluoromethoxy moiety with the hydroxyl group of the side chain of the gatekeeper threonine residue in SIKs.SAR exploration showed that the difluoromethoxy group and alkylation of the amide could enhance kinase selectivity; we hypothesize that the difference of gatekeeper residues and of flexibility of the P-loop between kinases account for the observed gain of selectivity through the generation of steric clashes.
Overall, the first experimentally determined crystal structure of SIK3 provides a unique contribution, opening new opportunities to explore the SIK family by enabling structure-based drug design, understanding the SAR within this chemical series and other known SIK inhibitors, structural comparison with other kinases to rationalize selectivity, and investigation of protein−protein interactions.
Optimization of Mouse Pharmacokinetic Properties.Following optimization of the potency on SIKs and off-target selectivity, pharmacokinetic properties in mice were investigated next to select a potent and selective lead molecule with low clearance and high oral bioavailability to explore the impact of SIK inhibition in vivo in mouse models after oral dosing.
As shown previously, compound 20 is a potent and selective SIK inhibitor with IC 50 values of 5.8 nM on SIK1, 2.3 nM on SIK2, and 1.0 nM on SIK3.Compound 20 displayed intrinsic unbound clearances of 7.16 and <1.93 L/h/kg in mouse microsomes and hepatocytes, respectively (Table 6).This good metabolic stability in vitro was suitable for in vivo characterization in mice.Following iv administration at 1 mg/ kg, the compound showed a moderate total plasma clearance of 2.33 L/h/kg but a high unbound clearance of 79.0 L/h/kg.A low oral bioavailability of 12% was determined following administration of an oral dose of 15 mg/kg.Compound 27 with a methyl group replacing the ethyl group on the pyrazole ring retains similar activity on SIKs with IC 50 values of 6.9 nM on SIK1, 3.3 nM on SIK2, and 1.1 nM on SIK3.Compound 27 showed good metabolic stability in vitro with intrinsic unbound clearances of <3.05 and <1.45 L/h/kg in mouse microsomes and hepatocytes, respectively.Following iv administration of 27 at 1 mg/kg, low total and moderate unbound plasma clearances of 0.758 and 22.3 L/h/kg, respectively, were observed.An oral bioavailability of 60% was determined following administration of an oral dose of 5 mg/kg of 27.Overall, compound 27 had similar potency as compound 20 against SIKs and improved pharmacokinetic properties with lower clearance and higher oral bioavailability than 20.Compound 28 with a cyclopropyl carboxamide replacing the ethyl carboxamide inhibits SIKs more potently than 27 with IC 50 values of 2.0 nM on SIK1, 0.7 nM on SIK2, and 0.6 nM on SIK3.Compound 28 displayed good metabolic stability in vitro with intrinsic unbound clearances of 4.76 and <1.75 L/h/ kg in mouse microsomes and hepatocytes, respectively.Following iv administration of 28 at 1 mg/kg, low total and unbound plasma clearances of 0.945 and 10.2 L/h/kg, respectively, were observed.An oral bioavailability of 60% was determined following administration of an oral dose of 5 mg/kg of 28.Overall, compound 28 displayed comparable pharmacokinetic properties to compound 27 with improved potency on SIKs.
In summary, starting from compound 20, shortening of the ethyl group on the pyrazole ring to a methyl group in compound 27 improved the in vivo total and unbound clearance and oral bioavailability.Then, replacement of ethyl carboxamide with cyclopropyl carboxamide in 28 enhanced activity on SIKs while retaining low plasma clearance and high oral bioavailability.Lead molecule 28, also called GLPG3312, exhibited the desired pharmacokinetic properties to explore SIK inhibition in vivo in mouse models.In vitro and in vivo properties of compound 28 were also further characterized to assess its suitability for preclinical development.
Rat and Dog Pharmacokinetics.Rats and dogs are the preferred species for in vivo toxicology investigations in preclinical development, and pharmacokinetic properties from several preclinical species are generally used to predict human pharmacokinetic properties.Thus, the pharmacokinetic properties of 28 were also evaluated in rats and dogs (Table 7).

Journal of Medicinal Chemistry
In rats, following iv administration at 1 mg/kg, 28 was characterized by a low total plasma clearance of 0.466 L/h/kg, a low unbound plasma clearance of 4.78 L/h/kg, and a moderate steady-state volume of distribution of 0.678 L/kg.The elimination half-life was 1 h.The absolute oral bioavailability was 41.4% after administration of an oral dose of 5 mg/kg.In dogs, following iv administration at 1 mg/kg, 28 was characterized by a low total plasma clearance of 0.332 L/ h/kg, a low unbound plasma clearance of 1.67 L/h/kg, and a large steady-state volume of distribution of 1.76 L/kg.The apparent elimination half-life was 5.1 h.The absolute oral bioavailability was 45.5% after 30 mg/kg oral dosing.Overall, compound 28 displayed low clearance and moderate to high oral bioavailability in mice, rats, and dogs.These pharmacokinetic properties were deemed suitable for further preclinical evaluation.
Kinase Selectivity Profile of 28.In addition to potent SIK inhibition and good pharmacokinetic properties, we aimed to identify a compound with good kinome selectivity to explore the therapeutic potential of SIK inhibition only.The inhibition of enzymatic activity by compound 28 at 1 μM was assessed against a panel of 380 kinases and is represented in Figure 5 (the percentage of inhibition for each kinase is available in the Supporting Information).Apart from SIKs, compound 28 showed higher than 80% inhibition at 1 μM on four other kinases: DDR1, LIMK1, MAP3K20, and RIPK2.Several kinases showed between 50 and 80% inhibition at 1 μM, and as shown in Table 8, IC 50 was determined for all offtargets with inhibition equal to or higher than 50% at 1 μM, and the fold shift versus IC 50 on SIK isoforms was calculated.RIPK2 was the most potent off-target identified for 28 with an IC 50 value of 19.7 nM.IC 50 on RIPK2 is approximately 10-fold less potent than that on SIK1 and 30-fold less potent than those on SIK2 and SIK3.The next most potent off-target kinase was DDR1 with an IC 50 value of 57 nM.IC 50 on DDR1 is approximately 30-fold less potent than that on SIK1 and more than 80-fold less potent than that on SIK2 and SIK3.
In summary, the profiling of compound 28 against a panel of 380 kinases at 1 μM showed excellent selectivity.RIPK2 was identified as the main off-target.Compound 28 is approximately 10-fold more potent on SIK1 than on RIPK2 and 30fold more potent on SIK2 and SIK3 than on RIPK2.Compound 28 is therefore a highly selective pan-SIK inhibitor suitable to investigate SIK pharmacology in vitro and in vivo.
Human In Vitro Pharmacodynamic Profile of 28.Myeloid cells, including monocytes and macrophages, play key roles during the initiation, propagation, and resolution of inflammation.Upon stimulation, myeloid cells can release proinflammatory (e.g., TNFα) and anti-inflammatory (e.g., IL-10) cytokines.We investigated the impact of SIK inhibition on cytokine release using compound 28 in in vitro cell assays using primary human monocytes and monocyte-derived macro- Fraction unbound in plasma is 0.0974 and 0.1991 in rats and dogs, respectively.phages (MdM) stimulated with LPS.In both cell types, 28 dose-dependently inhibited TNFα release, with average IC 50 values of 17 nM and 34 nM, respectively (Table 9).
Simultaneously, compound 28 enhanced the release of IL-10 in both cell types.Data on IL-10 are expressed as foldinduction versus LPS trigger at the top concentration of 20 μM evaluated in the assay, as inaccurate curve fitting on IL-10 induction across different experiments did not allow robust EC 50 determination.Compound 28 led to 14.8-and 2.8-fold average inductions of IL-10 at 20 μM relative to LPS-only conditions for monocytes and MdM, respectively (Figure 6 and Table 9).Generally, a higher magnitude of IL-10 induction was observed with compound 28 in monocytes compared with that in MdM.Although these observational results were not further studied, we hypothesize that differences in the expression of SIK isoforms or components of the SIK-mediated signal transduction pathway could serve as an explanation for the differences in the magnitude of IL-10 induction between both cell types.Moreover, as shown in the representative curves in Figure 6, the induction of IL-10 by compound 28 starts at higher concentrations than TNFα inhibition, which suggests that the required level of SIK inhibition might be different for the two activities.
Overall, compound 28 inhibited the production of TNFα and increased the release of IL-10 by primary human myeloid cells stimulated by LPS.Compound 28 therefore displays both anti-inflammatory and immunoregulatory activities in vitro.
Murine In Vivo Pharmacodynamic Profile of 28.To assess in vivo the effect observed on TNFα and IL-10 in vitro, we explored the activity of 28 in an in vivo acute LPS challenge model in mice.In this model, stimulation by LPS elicits an immune response with increased levels of TNFα and IL-10 circulating in blood.LPS was injected intraperitoneally 15 min after oral administration of 28 at doses of 0.3, 1, and 3 mg/kg or the corresponding vehicle.Blood was collected 1.5 h post-LPS stimulation, and levels of TNFα and IL-10 in plasma were quantified.As shown in Figure 7, 28 dose-dependently reduced the release of TNFα with 27.0, 57.2, and 77.5% inhibition at 0.3, 1, and 3 mg/kg, respectively, compared with vehicle in mice stimulated with LPS.28 also dose-dependently increased the plasma concentration of IL-10 by 1.3,-2.4-,and 3.1-fold at 0.3, 1, and 3 mg/kg, respectively, compared with the vehicle in mice stimulated with LPS.
In summary, compound 28 inhibited the production of TNFα and increased the release of IL-10 in mice stimulated with LPS.Compound 28 therefore displays both antiinflammatory and immunoregulatory activities in vivo.

■ CHEMISTRY
A general method for the preparation of benzimidazole derivatives is depicted in Scheme 1. 27,28 Nucleophilic aromatic substitution on 4-bromo-1-fluoro-2-nitrobenzene with the     selectivity against off-targets.No suitable aniline building block bearing the difluoromethoxy group was available; a dedicated synthesis of the required aniline moieties was therefore designed as shown in Scheme 5. Mono demethylation of commercially available 29 was performed with boron trichloride to generate phenol derivative 34, and the aniline group was then protected as a 2,5-dimethylpyrrole in 35. 29 Saponification of the methyl ester gave 36, which underwent amide coupling with ethyl amine and cyclopropyl amine to yield secondary amide intermediates 37a and 37b, respectively.Difluoromethylation of the phenol was performed using bromodifluoromethyl diethylphosphonate to give corresponding difluoromethoxy derivatives 38a and 38b. 30Dimethylpyrrole deprotection was performed with hydroxylamine in a refluxed mixture of ethanol and water, affording key aniline intermediates 39a and 39b.The same strategy as previously was used to construct the benzimidazole ring system.Nucleophilic aromatic substitution on 4-bromo-1-fluoro-2nitrobenzene with the anion of 39a and 39b gave intermediates 40a and 40b, respectively, and then reduction of the nitro group in the presence of zinc dust in acetic acid and cyclization with trimethyl orthoformate in methanol led to 5-bromobenzimidazole intermediates 41a and 41b.Finally, Suzuki coupling with methyl or ethyl pyrazole boronic acid pinacol ester reagents afforded compounds 20, 27 and lead molecule 28.

■ CONCLUSIONS
In summary, we have identified a series of highly potent and selective SIK inhibitors.Following an HTS campaign, a new chemotype displaying pan-SIK inhibition was identified, and SAR was explored to improve selectivity against a panel of kinases while improving potency against SIKs.The first crystal structure of SIK3 was generated, allowing a better understanding of the binding mode and selectivity of the chemical series.Optimization of pharmacokinetic properties finally led to pan-SIK inhibitor 28 (GLPG3312), which displayed low nanomolar IC 50 for the three SIK isoforms and excellent kinase selectivity.28 demonstrated a dual profile with both antiinflammatory and immunoregulatory activities in vitro in human primary innate immune cells stimulated with LPS and in vivo in mice challenged with LPS.28 was progressed into a phase 1 clinical trial evaluating a modified release exposure regimen (NCT03800472).In parallel, Galapagos investigated selective SIK2/SIK3 inhibitors and identified SIK1 inhibition as dispensable for the targeted pharmacology of SIK inhibitors.28 was superseded by a new selective SIK2/SIK3

Journal of Medicinal Chemistry
inhibitor candidate, GLPG3970, whose identification will be described in a future publication.
Chemistry.General Procedure A for Amide Bond Forming Reaction.To the carboxylic acid derivative (1.0 equiv) in dimethylformamide (DMF) (5−8 mL per mmol of carboxylic acid) at rt, triethylamine (TEA) or N,N diisopropylethylamine (DIPEA) (2−15.0equiv) and hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) (1.5 equiv) were added.The reaction mixture was stirred for 15 min, then alkylamine or alkylamine hydrochloride (1.2−10 equiv) was added, and stirred until full conversion (15 min− overnight).The reaction mixture was concentrated under a reduced pressure.The residue was diluted with dichloromethane (DCM) and NaHCO 3 aqueous saturated solution.The organic layer was separated, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.The crude residue was purified by flash chromatography on silica gel (eluting with a gradient of DCM/EtOAc) to afford the expected amide derivative.
Methyl 4-((4-Bromo-2-nitrophenyl)amino)-2,6-dimethoxybenzoate (30).Under a nitrogen atmosphere, a solution of lithium hexamethyldisilazane (LHMDS) in tetrahydrofuran (THF) (0.5 M, 109.02mL) was added dropwise over 2 h to a rapidly stirred solution of 4-methoxycarbonyl-3,5-dimethoxyaniline 29 (5.00 g, 23.70 mmol, 1.0 equiv) and 4-bromo-1-fluoro-2-nitrobenzene (5.21 g, 23.70 mmol, 1.0 equiv) in THF (125 mL), which was partially immersed in an icecold water bath.Upon completion of the addition, the dark purple solution was stirred for further 30 min, allowing the temperature to rise, and then the reaction was quenched with water (100 mL).THF was removed in vacuo, and then 2N HCl solution (50 mL) was added to the remaining rapidly stirred mixture.The resulting precipitate was isolated by filtration, washed with water, and dried under vacuum.The solid was then triturated with Et 2 O/hexane 60:40 and then dried under vacuum to give product 30 (8.46 g, 87% isolated yield) as a dark orange powder, which was used without further purification.LC−MS: (31).A mixture of nitro compound 30 (5.04 g, 12.29 mmol, 1.0 equiv), tin(II) chloride dihydrate (11.1 g, 49.2 mmol, 4.0 equiv), and ethanol (170 mL) was heated at 85 °C for 2.5 h.The mixture was cooled to rt, then trimethyl orthoformate (5.3 mL, 48.4 mmol, 3.9 equiv) was added, and the mixture was heated at 85 °C for 3.5 h.The mixture was cooled to rt, and the solvents were removed under reduced pressure.The residue was redissolved in ethyl acetate, and the solution was washed with 2 M aqueous sodium hydroxide solution, followed by saturated sodium bicarbonate solution and was then dried (MgSO 4 ).The solvent was removed under reduced pressure, and the dark purple residue was triturated with diethyl ether, filtered, and washed with diethyl ether to afford 31 as a purple solid (3.36 g, 70% isolated yield) used for the next step without further purification.LC−MS: m/z = 391.3,393.3 [M + H].

4-(5-Bromo-1H-benzo[d]
imidazol-1-yl)-2,6-dimethoxybenzoic acid (32).Methyl ester 31 (2.97 g, 7.61 mmol, 1.0 equiv) was dissolved in methanol (20 mL) and THF (30 mL), and 2 M aqueous sodium hydroxide (20 mL) was added.The reaction mixture was stirred overnight at 65 °C.The reaction mixture was cooled to rt, and the organic solvents were removed under reduced pressure.The aqueous suspension was diluted with water and acidified with dilute hydrochloric acid until a pH between 1 and 2 was reached.After cooling in ice for 1 h, the suspension was filtered, and the resulting solid was washed with water and dried in air to afford 32 as a purple solid (2.70 g, 94% isolated yield).LC−MS: m/z = 377.2,379.2 [M + H].

N-Cyclopropyl-2-(difluoromethoxy)-4-(2,5-dimethyl-1H-pyrrol-1yl)-6-methoxybenzamide (38b).
To a stirred solution of 37b (6.33 g, 21.07 mmol, 1.0 equiv) in acetonitrile (100 mL) at −10 °C, KOH (23.65 g, 421.40 mmol, 20 equiv) in water (100 mL) was added dropwise.The resulting mixture was stirred at −10 °C for 25 min, and bromodifluoromethyl diethylphosphonate (7.49mL, 42.14 mmol, 2 equiv) in acetonitrile (15 mL) was added dropwise (caution: exothermicity controlled by the addition rate).LC−MS analysis showed full conversion once the addition was completed.The mixture was quenched with ice water and extracted twice with DCM.The organic layers were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.The residue was purified on a 2 × 100 g HP column (Biotage) and eluted with 0−2% MeOH in DCM.The product fractions were combined and evaporated until dry to afford the title compound, 38b, as a light brown solid (6.78 g, 92% isolated yield). 1  4-Amino-2-(difluoromethoxy)-N-ethyl-6-methoxybenzamide (39a).To a stirred solution of 38a (5.35 g, 15.81 mmol, 1.0 equiv) in EtOH (60 mL) at rt, hydroxylamine hydrochloride (10.9 g, 151.8 mmol, 10.0 equiv) in water (30 mL) and triethylamine (4.37 mL, 31.62 mmol, 2.0 equiv) were added.The reaction mixture was refluxed overnight.EtOH was evaporated.The aqueous phase was brought to pH 10 with a Na 2 CO 3 saturated aqueous solution and extracted with DCM.The organic layers were dried over MgSO 4 , filtered, and concentrated under reduced pressure.The residue was purified by flash chromatography on silica gel and eluted with 0−5% MeOH in DCM.The product fractions were combined and evaporated until dry to afford the title compound as a beige solid, which was further purified by flash chromatography on a KP-NH column (Biotage) and eluted with 0−2% MeOH in DCM.The product fractions were combined and evaporated until dry to afford the title intermediate, 39a, as a white solid (3.08 g, 75% isolated yield). 1  4-Amino-N-cyclopropyl-2-(difluoromethoxy)-6-methoxybenzamide (39b).To a stirred solution of 38b (6.78 g, 19.35 mmol, 1.0 equiv) in EtOH (100 mL) at rt, hydroxylamine hydrochloride (13.45 g, 193.51 mmol, 10.0 equiv) in water (50 mL) was added.The reaction mixture was refluxed overnight.Hydroxylamine hydrochloride (6.72 g, 96.7 mmol, 5.0 equiv) and triethylamine (5.35 mL, 38.7 mmol, 2.0 equiv) were added.The reaction mixture was refluxed for 3.5 h.EtOH was evaporated.The aqueous phase was brought to pH 9 with NaOH 2N and was extracted twice with EtOAc.The organic layers were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.The residue was purified by chromatography on silica gel and eluted with 0−5% MeOH in DCM.The product fractions were combined and evaporated until dry.The solid was triturated with Et 2 O and filtered to afford the title intermediate, 39b (3.61 g, 68% isolated yield), as a white solid. 1
The final yield was 0.15 mg/L cell culture with a purity level of 85%.
ADP-Glo Kinase Assay with SIKs.1.11−2.23 nM SIK1, 0.11− 0.48 nM SIK2, or 0.45 nM SIK3 was incubated with 45 μM AMARA peptide and 5 μM ATP in 25 mM Tris pH 7.5, 0.5 mM EGTA, 0.01% Triton X-100, 5 mM MgCl 2 , and 2.5 mM DTT at rt for 120 min in the presence or absence of the compound.To determine IC 50 values, compounds were tested in a 10-point dose response with a 1/5 serial dilution starting from a top concentration of 20 μM.The kinase reaction was stopped after the addition of an equal volume of ADP-Glo reagent (ADP-Glo Kinase Assay, Promega, NL) and was incubated at rt for 40 min to remove all the remaining ATP.Afterward, a double volume of kinase detection reagent was added and incubated for a minimum of 30 min at rt before the luminescence signal was measured with an EnVision PerkinElmer plate reader.
General Procedure for 33 P Radioactive Kinase Assay.The basis for the radioactive kinase assay is the measurement of the incorporated 33 P into the substrate when phosphorylated by the kinase of interest using [ 33 P]-γ-ATP.Briefly, the kinase of interest was incubated with the substrate, ATP, and [ 33 P]-γ-ATP (PerkinElmer NV, BE) in the reaction medium at 33 °C for 45−60 min in the presence or absence of compound.To determine IC 50 values, compounds were tested in a 10-point dose response with a 1/5 serial dilution starting from a top concentration of 20 μM.The kinase reaction was stopped after the addition of an equal volume of 150 mM phosphoric acid. 33P that had not been incorporated was removed by loading the samples on a filter plate (UniFilter-96 GF/B, PerkinElmer NV, BE), followed by six subsequent washing steps with 75 mM phosphoric acid.Incorporated 33 P in the substrate was measured on a TopCount reader after the addition of MicroScint-20 (PerkinElmer NV, BE) to the filter plates.
Specific conditions for each kinase are listed in Table 10.Mouse Pharmacokinetics.A total of nine male CD1 mice were given compounds via either a single intravenous bolus at 1 mg/kg or oral administration at 5 or 15 mg/kg to assess absolute bioavailability.One group of six mice was dosed intravenously with a dose level of 1 mg/kg, and one group of three mice was dosed orally via a single gavage with a dose level of 5 or 15 mg/kg.The mice were fasted before oral administration.For the iv route, the compound was formulated as a solution in polyethylene glycol (PEG) 200 and water for injection (60/40; v/v).For the oral route, the compound was formulated as a homogeneous suspension in Solutol/methyl cellulose (MC) 0.5% (2/98; v/v).Blood was sampled under light gaseous anesthesia into polypropylene tubes containing lithium heparin, and plasma was prepared.The compound was quantified in plasma using LC−MS/MS.Pharmacokinetic parameters were calculated using Phoenix software (Certara, version 6.4.0.768).
Rat Pharmacokinetics.A total of six male Sprague−Dawley rats were given 28 either as a single intravenous bolus at 1 mg/kg or as an oral administration at 5 mg/kg to assess absolute bioavailability.One group of three rats was dosed intravenously with 28 at a dose level of 1 mg/kg, and one group of three rats was dosed orally with 28 via a single gavage with a dose level of 5 mg/kg.The rats were fasted before oral administration.For the iv route, 28 was formulated in polyethylene glycol (PEG) 200 and water for injection (60/40; v/ v).For the oral route, 28 was formulated in Solutol/MC 0.5% (2/98; v/v).Blood was sampled under light gaseous anesthesia into polypropylene tubes containing lithium heparin, and plasma was prepared.28 was quantified in plasma using LC−MS/MS.Pharmacokinetic parameters were calculated using Phoenix software (Certara, version 6.4.0.768).Dog Pharmacokinetics.One group of three male Beagle dogs was dosed intravenously via a 10 min infusion of 28 with a dose level of 1 mg/kg.After a washout period of 3 days, the same three dogs were dosed orally with 28 via a single gavage with a dose level of 5 mg/kg and, after a washout period of 5 days, were dosed orally via a single gavage with a dose level of 30 mg/kg.For the iv route, 28 was formulated in PEG 200 and H 2 O for injection (60/40; v/v).For the In Vitro LPS-Triggered Human Primary Monocyte Assay.The activity of 28 was evaluated on LPS-stimulated cytokine production in monocytes.Peripheral blood mononuclear cells (PBMCs) were first isolated from blood using Lymphoprep-based separation, a method which is based on the lower buoyant density of mononuclear cells (monocytes and lymphocytes) compared with other blood cell types such as erythrocytes and polymorphonuclear leukocytes (granulocytes).From these PBMCs, CD14+ monocytes were selected using antibody-coated magnetic beads (Miltenyi Biotec, DE).CD14+ monocytes were seeded in 96-well plates and preincubated with a serial dilution of 28 for 1 h before LPS triggering (Sigma-Aldrich; 100 ng/mL final concentration).TNFα and IL-10 were measured in the supernatant after 4 h of LPS triggering using enzyme-linked immunosorbent assay (ELISA)-based readouts.
In Vitro LPS-Triggered Human Primary MdM Assay.To evaluate 28 in MdM, CD14 + monocytes (isolated as described above) were further differentiated toward macrophages using macrophagecolony stimulating factor (M-CSF [ImmunoTools]); 100 ng/mL final concentration) over 10 days.Differentiated MdM were preincubated with a serial dilution of 28 for 1 h before LPS triggering (100 ng/mL final concentration).The supernatant was collected at 2 h for IL-10 and 20 h for TNFα after LPS triggering, and cytokine levels were measured by using ELISA-based readouts.
In Vivo Mouse LPS Challenge.28 was prepared in Solutol/MC 0.5% (2/98; v/v) the day before administration and gently mixed at rt in the dark overnight.Then, it was administered orally to Balb/c mice at 0.3, 1, and 3 mg/kg.Fifteen minutes later (corresponding to the T max of the pharmacokinetics of 28), 100 μg of LPS (in 0.2 mL of H 2 O) was injected intraperitoneally to mice.A control group was included with Solutol/MC 0.5% (2/98; v/v) p.o. without LPS challenge.Mice were sacrificed 1.5 h after LPS challenge, and blood was collected by carotid exsanguination in heparinized tubes.Plasma samples were obtained by centrifugation for 15 min and 2000g at +4 °C and frozen at −80 °C before cytokine quantifications.IL-10 and TNFα were quantified by AlphaLISA according to the manufacturer's instructions.Optical densities were determined using EnVision (PerkinElmer).
Statistical analysis was performed on raw data or log-transformed data.The normality of residuals and the equality of variances for a parametric analysis were checked.Means were compared by one-way ANOVA and Dunnett's post hoc test.Statistical analyses were done versus the LPS/vehicle group (*** p < 0.001; ** p < 0.01; and * p < 0.05).
SIK3 Kinase−UBA Preparation, Crystallization, and Structure Determination.The coding sequence from amino acids 60− 394 of the human SIK3 protein (ref seq: NM_025164.6 and UniProtKB/Swiss-Prot Q9Y2K2-5) was mutated on residue 221 (T221D) and cloned into pFastBac1 with N-ter 6 histidine (6His) affinity tag and thrombin (Thr) protease sites giving pFastBac-6His-Thr-hsSIK3[60−394]T221D.The choice to remove the first 59 residues was motivated by the fact that this disordered sequence is not found in mouse and rat SIK3 orthologues nor human SIK1 and SIK2 proteins.The protein was expressed in the same manner as for fulllength SIK3.For cell lysis, the pellet was resuspended in 25 mM Tris-HCl pH 8.0, 250 mM NaCl, 2 mM MgCl 2 , 25 mM imidazole, 1 mM DTT, and 10% v/v glycerol and was supplemented with two EDTAfree protease inhibitor cocktail tablets.The whole cell lysate was incubated at 4 °C for 1 h.Cells were lysed by sonication, and the lysate was cleared by centrifugation.For IMAC affinity chromatography, the soluble fraction was added to Ni-NTA resin (2.4 mL resin/ 200 mL lysate) and batch-bound overnight at 4 °C with rotation.Protein was eluted from the resin with a 25 mM−1 M imidazole gradient.Eluate samples were applied to an S200 size exclusion column, equilibrated in 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM MgCl 2, and 0.5 mM Tris(hydroxypropyl)phosphine (THP).Peak fractions were pooled and concentrated to an ∼3 mL volume.Compound 22 described above was added at a final concentration of 20 μM, and the solution was left on ice overnight.The protein complex was concentrated further to 5 mg/mL for crystallization.
Crystals were grown at 9 °C in 12% (w/v) PEG 3350 and 0.1 M sodium citrate pH 7.0.Crystals were transferred to a solution containing mother liquor supplemented with 20% (v/v) glycerol as a cryoprotectant prior to cryocooling in liquid nitrogen.Data sets were collected by using a Dectris Pilatus 6 M detector on beamline i03 at the DLS synchrotron (Table 11).Data were indexed, integrated, and scaled using MOSFLM and AIMLESS (CCP4).MARK2 coordinates were downloaded (PDB ID: 2R0I), and Chain A was prepared for molecular replacement in PHASER (CCP4).A single solution was found by PHASER containing two SIK3 molecules per asymmetric unit.The protein sequence was mutated to match that of SIK3 by using CHAINSAW (CCP4), and the model was improved iteratively through successive cycles of model building and refinement.The molecular structure of 22 and refinement library files were produced using JLigand (CCP4).The ligand was fitted into the difference electron density in the ATP pocket by using COOT and refined by using REFMAC5 (CCP4).
Molecular Modeling.All molecular modeling calculations were carried out using the Schrodinger software suite (Schrodinger Release 2018−1, Schrodinger, LLC, New York, USA).
Ligand Docking.All docked compounds were built and protonated using LigPrep, 31 whereas ionization states at pH between 5 and 9 were calculated with Epik. 32The crystal structure of AMPK1 was taken from the RCSB protein databank (PDB code: 4RER 33 ).
For both AMPK1 and the internal SIK3 X-ray structure, hydrogen atoms were added to the protein through the Protein Preparation Wizard tool. 34In order to optimize the hydrogen bond network, the

Journal of Medicinal Chemistry
most putative protonation state of the residues was carefully selected by visual inspection, and hydrogen atoms were minimized using the OPLS3 force field. 35Before the docking procedure was run, all water molecules present in the PDB were removed.Docking of the ligands was carried out with Glide. 36A docking grid was generated using AMPK1 or SIK3 prepared structures.The cocrystallized ligand was selected as the center of the grid, and a hydrogen bond constraint with the hinge hydrogen bond donor (Ala145 NH for SIK3 and Val98 NH for AMPK1) was created, whereas the rest of the settings were kept as default.These constraints were used as these two hydrogen bond interactions are the main ones fixing the scaffold close to the hinge.For the docking run, the flexible docking standard precision option was selected together with an enhanced sampling protocol (four times) of the ligands.The constraint was applied to all docking runs, whereas the number of poses to return was set as three for each ligand.
The binding modes were then selected based on spatial geometries of the ligand within the binding cavity and complementarity with the pocket (shape and electrostatic complementarity).
Individual percentage of kinase inhibition by 28 at 1 and 0.1 μM; crystal structure; and NMR spectra and HPLC traces of the synthesized compounds (PDF) Molecular formula strings with associated data (CSV)

Accession Codes
The crystal structure reported here has been deposited in the Protein Data Bank with the following accession code: 8OKU.Authors will release the atomic coordinates and experimental data upon article publication.

Figure 1 .
Figure 1.Structures of SIK inhibitors described in the literature and of GLPG3312 (28).

Figure 2 .
Figure 2. (A) Crystal structure of SIK3 (60−394 T221D) in a complex with 22.The N-and C-lobes of the kinase domain are colored cyan and dark blue, respectively, with 22 (pink) binding in the catalytic pocket.The UBA domain, colored red, is connected to the kinase domain via a linker (gray) and packs against the kinase N-lobe.(B) Crystal structure of SIK3 (gray) around the binding site of 22 (pink), highlighting important regions such as P-loop (green), αC-helix-in (red), DFG-in motif (blue), and A-loop (orange).(C) Interface between kinase domain and linker region connecting to the UBA domain, colored as in (A).Key residues are shown as sticks and labeled.Hydrogen bond interactions are presented as dashed lines.(D) Interface between the N-lobe of the kinase domain and UBA domain.(E) Same region as (D) but rotated 90 deg.(F) Superimposition of SIK3 (gray) with 22 (pink) and MARK4 (green, PDB ID: 5ES1), RMSD: 0.82 Å.

Figure 3 .
Figure 3. X-ray structure of 22 in complex with SIK3 (3.1 Å resolution).SIK3 is represented as a gray cartoon, with key interacting residues as gray sticks.Compound 22 is shown as pink sticks.Hydrogen bond interactions are shown as dotted yellow lines.A feature-enhanced map contoured at 1.0σ around the ligand is displayed as a blue mesh.The tip of the ligand hydroxyethyl chain is not well resolved, and the hydroxyl group is suitably positioned to form hydrogen bonds with either the backbone carbonyl of Ser146 or the side chain of Tyr144.

Figure 4 .
Figure 4. (A) Docking pose of compound 20 (shown as green sticks) in SIK3.(B) Docking pose of compound 15 (shown as orange sticks) in SIK3.(C) Docking pose of compound 20 (shown as green sticks) in AMPK (PDB ID 7JHG).(D) Docking pose of compound 15 (shown as orange sticks) in AMPK (PDB ID 7JHG).Zoom-in view of the back-pocket.The surfaces of 20 and 15 are represented in blue, while the surfaces of Thr142 and Met95 are shown in black.The steric hindrance between Met95 and the OCHF 2 group is highlighted with an orange dashed line.

a
Levels of TNFα and IL-10 measured 4 h post-stimulation with LPS were compared with LPS-only conditions (n = 6).b Levels of TNFα (n = 5) and IL-10 (n = 4) were measured at 20 and 2 h post-LPS stimulation, respectively, and compared with LPS-only conditions at the same time point.Donors for which no accurate calculation of IC 50 was possible on TNFα (1 donor) or that displayed a lower response of positive control than expected on IL-10 (n = 2) were excluded.

Figure 6 .
Figure 6.Effects of 28 on IL-10 and TNFα production in LPS-stimulated human monocytes (A) and MdM (B) from representative experiments.

Figure 7 .
Figure 7. Plasma levels of TNFα and IL-10 after an in vivo LPS challenge and oral administration of 28.Scheme 1. Preparation of Primary Amide Derivatives 9 and 10 a

Scheme 3 .
Scheme 3. Preparation of Secondary and Tertiary Amide Derivatives 14−19 a
,i is the intensity v a l u e o f t h e i t h m e a s u r e m e n t o f h

Table 1 .
Potency and Selectivity of SIK Inhibitors

Table 2 .
Hit Identification and Preliminary SAR Optimization−Activity of Compounds 8, 9, and 10

Table 3 .
Analogues with Replacement of the Carboxamide Group

Table 4 .
Exploration of Carboxamide Alkylation

Table 5
. Exploration of Pyrazole AlkylationJournal of Medicinal Chemistry the three isoforms.Similarly, additional alkylation on the carboxamide with a methyl group in 19 led to a more than 100-fold drop of potency against SIKs, which could be due to a steric clash or loss of the hydrogen bond donor capacity of the

Table 6 .
Pharmacokinetics in Mice and the Structure−Property Relationship aFraction unbound in mouse plasma is 0.0295, 0.034, and 0.093 for 20, 27, and 28, respectively.

Table 7 .
Pharmacokinetics of 28 in Rats and Dogs

Table 8 .
Potency of 28 on Off-Targets from a 380 Kinase Panel Inhibited by 50% or More at 1 μM of 28 and Fold Shift versus Potency on SIK1, SIK2, and SIK3

Table 10 .
Conditions for Radioactive Kinase Assays 28 was formulated in Solutol/MC 0.5% (2/98; v/v).The dogs were fasted before intravenous and oral administration.Blood was sampled without anesthetic from a jugular vein into lithium heparin tubes.Plasma was prepared, and 28 was quantified using LC− MS/MS.Pharmacokinetic parameters were calculated using Phoenix software (Certara, version 6.4.0.768).

Table 11 .
X-ray Crystallographic Data for Compound 22 a Diamond Light Source (Oxfordshire, United Kingdom).b Values in parentheses refer to the highest resolution bin.c where I h,i is the i n t e n s i t y v a l u e o f t h e i t h m e a s u r e m e n t o f h